导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.65% | 3289/4773 |
| 近一周 | -0.76% | 249/5462 |
| 近一月 | 1.66% | 329/5421 |
| 近一季 | 2.03% | 501/5209 |
| 近半年 | -3.49% | 2226/4920 |
| 近一年 | -5.21% | 3142/4366 |
| 近两年 | 21.18% | 2626/2954 |
| 近三年 | 16.19% | 1608/2253 |
| 成立以来 | 45.75% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.24% 3571/4961 |
-8.86% 3927/5312 |
- - |
- - |
| 2025 | 4.06% 3076/4813 |
-2.72% 2963/3635 |
5.40% 599/4076 |
-0.68% 3937/4524 |
2.19% 1053/4813 |
| 2024 | 27.79% 178/3463 |
7.81% 220/2808 |
2.88% 302/3014 |
15.98% 1574/3129 |
-0.66% 1492/3463 |
| 2023 | 0.05% 427/2656 |
4.54% 925/2280 |
2.08% 168/2385 |
1.93% 266/2515 |
-8.02% 2233/2655 |
| 2022 | -2.78% 60/2207 |
-1.11% 139/1919 |
1.58% 1452/2016 |
-6.78% 108/2113 |
3.83% 631/2208 |
| 2021 | -2.00% 832/1822 |
3.23% 191/1255 |
-4.58% 1263/1330 |
-0.82% 503/1466 |
0.30% 1140/1822 |
| 2020 | 2.46% 918/1250 |
-13.01% 914/1028 |
1.27% 990/1067 |
8.04% 740/1164 |
7.65% 701/1184 |
| 2019 | 20.84% 658/1092 |
15.62% 682/754 |
1.38% 130/804 |
-1.65% 672/850 |
4.82% 776/918 |
| 2018 | - - |
- - |
- - |
- - |
-9.75% 161/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 嘉实基本面50指数(LOF)C VS. 长安沪深300非周期A(740101) |